Follow-The-Filings

Security · featured owners

ALLO Allogene Therapeutics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 0.8%
  • $4M
  • 1 add 1 reduce

ALLO (Allogene Therapeutics Inc.) is held in 2 featured 13F books as of 2026 Q2. Nathan Fischel - Dafna Capital Management is the largest tracked holder by portfolio weight (0.79%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.8% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel add 0.79%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Nathan Fischel - Dafna Capital Management 2026 Q2 0.79% Add +46.0% 2,000,000 $4M history
Murray Stahl - Horizon Kinetics Asset Management 2026 Q2 <0.01% Reduce −4.6% 16,776 $35K history

2 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 18 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B5 Filing Doc
8-K 5.07,8.01 Filing Doc
8-K 5.02 Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
8-K 1.01,1.02,2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
424B5 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 9 rows shown

Filed Form Detail Links
4 Period Aug 21, 2026 Filing Doc
4 Period Jul 1, 2026 Filing Doc
4 Period Jun 18, 2026 · 7 forms Filing Doc
4 Period Apr 21, 2026 Filing Doc
4 Period Mar 31, 2026 Filing Doc
4 Period Mar 16, 2026 · 2 forms Filing Doc
4 Period Mar 2, 2026 Filing Doc
4 Period Feb 2, 2026 · 7 forms Filing Doc
4 Period Jan 21, 2026 Filing Doc

Updated 5 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $95,000 $22,000 $0.00
Net income -$327.26M -$257.59M -$190.89M
Net margin * -344489.5% -1170863.6% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $481.46M $303.39M $257.75M
Total non-current assets * $268.66M $245.32M $158.16M
Total assets $750.13M $548.71M $415.9M
Total current liabilities $59.4M $35.52M $32.51M
Total non-current liabilities * $98.72M $91.01M $90.85M
Total equity $592.01M $422.18M $292.54M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$237.73M -$200.3M -$149.25M
Cash from investing $163.29M $75.69M $95.56M
Cash from financing $95.7M $116.68M $30.16M
Net change in cash $21.25M -$7.94M -$23.53M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders